Resilience of the Dutch HPV-based cervical screening programme during the COVID-19 pandemic

被引：2
作者：
Olthof, E. M. G. [1 ,4 ]
Aitken, C. A. [1 ,2 ]
Siebers, A. G. [3 ]
van Kemenade, F. J. [2 ]
de Kok, I. M. C. M. [1 ]
机构：
[1] Erasmus MC Univ Med Ctr Rotterdam, Dept Publ Hlth, Rotterdam, Netherlands
[2] Erasmus MC Univ Med Ctr Rotterdam, Dept Pathol, Rotterdam, Netherlands
[3] PALGA Fdn, Dutch Nationwide Pathol Databank, Houten, Netherlands
[4] Molewaterpl 40, NL-3015 GD Rotterdam, Netherlands
来源：
PUBLIC HEALTH | 2024年 / 227卷
关键词：
Cervical cancer screening; Resilience; HPV screening; COVID-19; Suspension; Self-sampling; COVERAGE;
D O I：
10.1016/j.puhe.2023.11.026
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
Objectives: Organisation of a screening programme influences programme resilience to a disruption as COVID-19. Due to COVID-19, the Dutch human papillomavirus-based cervical screening programme was temporarily suspended. Afterwards, multiple measures have been taken to catch-up participation. This study aimed to investigate programme resilience by examining the effect of COVID-19 and programme measures taken on participation in cervical screening.Study design: Observational cohort study.Methods: Data from the national screening registry and Dutch nationwide pathology databank (Palga) were used on invitations and follow-up in 2018/2019 (pre-COVID) and 2020 (COVID). Sending invitations, reminders and self-sampling kits were suspended from March to July 2020. Main outcome measures include distribution of participant characteristics (age, region and screening history), participation rates by age and region, time between invitation and participation (i.e. response time) and self-sampling use per month.Results: Participation rate was significantly lower in 2020 (49.8%) compared to 2018/19 (56.8%, P < 0.001), in all ages and regions. Compared to 2018/19, participation rates decreased most in women invited from January to March 2020 (-6.7%, -9.1% and -10.4%, respectively). From August, participation rates started to recover (difference between -0.8% and -2.7%). Median response time was longer in February and March (2020: 143 and 173 days; 2018/19: 53 and 55 days) and comparable from July onwards (median difference 0-6 days). Self-sampling use was higher in 2020 (16.3%) compared to 2018/ 19 (7.6%).Conclusions: The pandemic impacted participation rates in the Dutch cervical screening programme, especially of women invited before the programme pause. Implementation of self-sampling in national cervical screening programmes could increase participation rates and could serve as an alternative screening method in times of exceptional health care circumstances, such as a pandemic. Due to the well-organised programme and measures taken to catch-up participation, the impact of COVID-19 on the screening programme remained small.(c) 2023 The Author(s). Published by Elsevier Ltd on behalf of The Royal Society for Public Health.
引用
收藏
页码：42 / 48
页数：7
相关论文
共 23 条
  • [1] Introduction of primary screening using high-risk HPV DNA detection in the Dutch cervical cancer screening programme: a population-based cohort study
    Aitken, Clare A.
    van Agt, Heleen M. E.
    Siebers, Albert G.
    van Kemenade, Folkert J.
    Niesters, Hubert G. M.
    Melchers, Willem J. G.
    Vedder, Judith E. M.
    Schuurman, Rob
    van den Brule, Adriaan J. C.
    van der Linden, Hans C.
    Hinrichs, John W. J.
    Molijn, Anco
    Hoogduin, Klaas J.
    van Hemel, Bettien M.
    de Kok, Inge M. C. M.
    [J]. BMC MEDICINE, 2019, 17 (01)
  • [2] Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples: updated meta-analyses
    Arbyn, Marc
    Smith, Sara B.
    Temin, Sarah
    Sultana, Farhana
    Castle, Philip
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2018, 363
  • [3] Cervical screening coverage in England before and during COVID-19
    Armitage, R.
    [J]. PUBLIC HEALTH, 2021, 198 : E11 - E11
  • [4] The impact of COVID-19 on national screening programmes in England
    Armitage, R. C.
    Morling, J. R.
    [J]. PUBLIC HEALTH, 2021, 198 : 174 - 176
  • [5] Cervical screening during the COVID-19 pandemic: optimising recovery strategies
    Castanon, Alejandra
    Rebolj, Matejka
    Burger, Emily Annika
    de Kok, Inge M. C. M.
    Smith, Megan A.
    Hanley, Sharon J. B.
    Carozzi, Francesca Maria
    Peacock, Stuart
    O'Mahony, James F.
    [J]. LANCET PUBLIC HEALTH, 2021, 6 (07) : E522 - E527
  • [6] Key indicators of organized cancer screening programs: Results from a Delphi study
    Csanadi, Marcell
    de Kok, Inge M. C. M.
    Heijnsdijk, Eveline A. M.
    Anttila, Ahti
    Heinavaara, Sirpa
    Pitter, Janos G.
    Szeles, Gyorgy
    Ivanus, Urska
    Priaulx, Jennifer
    Veerus, Piret
    Senore, Carlo
    de Koning, Harry J.
    Voko, Zoltan
    [J]. JOURNAL OF MEDICAL SCREENING, 2019, 26 (03) : 120 - 126
  • [7] The Impact of the COVID-19 Pandemic and the Associated Belgian Governmental Measures on Cancer Screening, Surgical Pathology and Cytopathology
    de Pelsemaeker, Marie-Caroline
    Guiot, Yves
    Vanderveken, Jonathan
    Galant, Christine
    Van Bockstal, Mieke Rosalie
    [J]. PATHOBIOLOGY, 2021, 88 (01) : 46 - 55
  • [8] COVID-19 impact on screening test volume through the National Breast and Cervical Cancer early detection program, January-June 2020, in the United States
    DeGroff, A.
    Miller, J.
    Sharma, K.
    Sun, J.
    Helsel, W.
    Kammerer, W.
    Rockwell, T.
    Sheu, A.
    Melillo, S.
    Uhd, J.
    Kenney, K.
    Wong, F.
    Saraiya, M.
    Richardson, L. C.
    [J]. PREVENTIVE MEDICINE, 2021, 151 : 106559
  • [9] Gezondheidsraad, 2021, Verbetermogelijkheden bevolkingsonderzoek baarmoederhalskanker
  • [10] IKNL, 2021, MONITOR BEVOLKINGSON
123